{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:53:19Z","timestamp":1781628799948,"version":"3.54.5"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) v2.0 is a 14-item patient-reported outcome measure for assessing the daytime symptoms and impacts of insomnia. Content validity and measurement properties of the IDSIQ have been established among English-speakers. This study assessed content validity of translations of the IDSIQ, generated for use in clinical trials in non-English-speaking countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a cross-sectional, non-interventional, qualitative study in adults with insomnia from Denmark, Germany, Poland, and Spain. During one-on-one telephone interviews in their local language, participants answered the IDSIQ questions and described their overall impressions of the measure\u2019s clarity, length, recall period, and comprehensiveness, as well as the overall relevance of the IDSIQ items to their experience of daytime symptoms and impacts of insomnia. They also explained their interpretation of each IDSIQ item (i.e., what they were thinking when they answered the question) and provided feedback on item clarity and the response options. Interview transcripts were translated into English and analyzed using ATLAS.ti.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty adults with insomnia were interviewed (five per study country, average age 46.5 years). Most participants were female (75%) and were currently receiving treatment for insomnia (70%). All participants reported that the IDSIQ instructions were clear; almost all participants reported that they understood the individual IDSIQ items (95%) and that the number of items was appropriate (95%). While 60% of participants considered \u201ctoday\u201d an appropriate recall period, 35% suggested that a longer timeframe could also be useful. Most participants reported that the IDSIQ was comprehensive in its coverage of insomnia-related experiences (80%) and that the IDSIQ items collectively were relevant to their experiences of insomnia (80%). For each item, \u2265\u200985% of participants felt that the wording was clear and \u2265\u200975% of participants would not make any changes to the response options.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, participants in European countries representing differing languages and cultures considered the IDSIQ clear, comprehensive, and relevant to their experience of daytime symptoms and impacts of insomnia. Moreover, participant feedback indicated understanding of individual items as intended. These findings support content validity of the IDSIQ after its translation into different European languages, as well as its use in future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-025-00972-4","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T23:20:03Z","timestamp":1767050403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Confirming content validity of The Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) among adults with insomnia in four European countries"],"prefix":"10.1186","volume":"9","author":[{"given":"Andrea","family":"Phillips-Beyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane K.","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Kleinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"972_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/s1389-9457(00)00065-4","volume":"2","author":"CH Bastien","year":"2001","unstructured":"Bastien CH, Vallieres A, Morin CM (2001) Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2:297\u2013307. https:\/\/doi.org\/10.1016\/s1389-9457(00)00065-4","journal-title":"Sleep Med"},{"key":"972_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s40266-022-00977-4","volume":"39","author":"I Fietze","year":"2022","unstructured":"Fietze I, Bassetti CLA, Mayleben DW, Pain S, Seboek Kinter D, McCall WV (2022) Efficacy and safety of Daridorexant in older and younger adults with insomnia disorder: A secondary analysis of a randomised Placebo-Controlled trial. Drugs Aging 39:795\u2013810. https:\/\/doi.org\/10.1007\/s40266-022-00977-4","journal-title":"Drugs Aging"},{"key":"972_CR3","volume-title":"ATLAS.ti 8 windows user manual","author":"S Friese","year":"2019","unstructured":"Friese S, Ringmayr TG (2019) ATLAS.ti 8 windows user manual. ATLAS.ti Scientific Software Development GmbH, Berlin, Germany"},{"key":"972_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40271-020-00474-z","volume":"14","author":"S Hudgens","year":"2021","unstructured":"Hudgens S, Phillips-Beyer A, Newton L, Seboek Kinter D, Benes H (2021) Development and validation of the insomnia daytime symptoms and impacts questionnaire (IDSIQ). Patient 14:249\u2013268. https:\/\/doi.org\/10.1007\/s40271-020-00474-z","journal-title":"Patient"},{"key":"972_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","volume":"21","author":"E Mignot","year":"2022","unstructured":"Mignot E et al (2022) Safety and efficacy of Daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol 21:125\u2013139. https:\/\/doi.org\/10.1016\/S1474-4422(21)00436-1","journal-title":"Lancet Neurol"},{"key":"972_CR6","doi-asserted-by":"publisher","first-page":"e68967","DOI":"10.1371\/journal.pone.0068967","volume":"8","author":"E van Sonderen","year":"2013","unstructured":"van Sonderen E, Sanderman R, Coyne JC (2013) Ineffectiveness of reverse wording of questionnaire items: let\u2019s learn from cows in the rain. PLoS ONE 8:e68967. https:\/\/doi.org\/10.1371\/journal.pone.0068967","journal-title":"PLoS ONE"},{"key":"972_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1509\/jmr.11.0368","volume":"49","author":"B Weijters","year":"2012","unstructured":"Weijters B, Baumgartner H (2012) Misresponse to reversed and negated items in surveys: a review. J Mark Res 49:737\u2013747","journal-title":"J Mark Res"},{"key":"972_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","volume":"8","author":"D Wild","year":"2005","unstructured":"Wild D et al (2005) Principles of good practice for the translation and cultural adaptation process for Patient-Reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 8:94\u2013104. https:\/\/doi.org\/10.1111\/j.1524-4733.2005.04054.x","journal-title":"Value Health"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00972-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-025-00972-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-025-00972-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:56:55Z","timestamp":1781625415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-025-00972-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1186\/s41687-025-00972-4","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received ethics committee approval in each participating country. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AP-B. is the director of Innovus Consulting Ltd, which received financial support from Idorsia for work on this study. AKK and LK were employees of Evidera at the time of the study. Evidera received financial support from Idorsia (via Innovus) for work on this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}